Literature DB >> 25704640

PfRH5 as a candidate vaccine for Plasmodium falciparum malaria.

Damien R Drew1, James G Beeson2.   

Abstract

PfRH5 has recently emerged as a strong vaccine candidate for Plasmodium falciparum malaria. Antibodies inhibit invasion of erythrocytes by merozoites and blood-stage replication, and PfRH5 is a significant target of acquired human immunity. Recent studies have shown protective efficacy of PfRH5 vaccines in a non-human primate model of malaria.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  PfRH5; Plasmodium falciparum; invasion; malaria; vaccines

Mesh：

Substances：

Year:  2015        PMID： 25704640     DOI： 10.1016/j.pt.2015.02.001

Source DB:  PubMed          Journal:  Trends Parasitol        ISSN： 1471-4922


  10 in total

1.  Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions.

Authors:  Ruth O Payne; Sarah E Silk; Sean C Elias; Kazutoyo Miura; Ababacar Diouf; Francis Galaway; Hans de Graaf; Nathan J Brendish; Ian D Poulton; Oliver J Griffiths; Nick J Edwards; Jing Jin; Geneviève M Labbé; Daniel Gw Alanine; Loredana Siani; Stefania Di Marco; Rachel Roberts; Nicky Green; Eleanor Berrie; Andrew S Ishizuka; Carolyn M Nielsen; Martino Bardelli; Frederica D Partey; Michael F Ofori; Lea Barfod; Juliana Wambua; Linda M Murungi; Faith H Osier; Sumi Biswas; James S McCarthy; Angela M Minassian; Rebecca Ashfield; Nicola K Viebig; Fay L Nugent; Alexander D Douglas; Johan Vekemans; Gavin J Wright; Saul N Faust; Adrian Vs Hill; Carole A Long; Alison M Lawrie; Simon J Draper
Journal:  JCI Insight       Date:  2017-11-02

2.  Antibodies to Plasmodium vivax reticulocyte binding protein 2b are associated with protection against P. vivax malaria in populations living in low malaria transmission regions of Brazil and Thailand.

Authors:  Wen-Qiang He; Stephan Karl; Michael T White; Wang Nguitragool; Wuelton Monteiro; Andrea Kuehn; Jakub Gruszczyk; Camila T França; Jetsumon Sattabongkot; Marcus V G Lacerda; Wai-Hong Tham; Ivo Mueller
Journal:  PLoS Negl Trop Dis       Date:  2019-08-19

Review 3.  The Search of a Malaria Vaccine: The Time for Modified Immuno-Potentiating Probes.

Authors:  José Manuel Lozano; Zully Rodríguez Parra; Salvador Hernández-Martínez; Maria Fernanda Yasnot-Acosta; Angela Patricia Rojas; Luz Stella Marín-Waldo; Juan Edilberto Rincón
Journal:  Vaccines (Basel)       Date:  2021-02-02

4.  APC-Targeted DNA Vaccination Against Reticulocyte-Binding Protein Homolog 5 Induces Plasmodium falciparum-Specific Neutralizing Antibodies and T Cell Responses.

Authors:  Louise Bjerkan; Ganesh Ram R Visweswaran; Arnar Gudjonsson; Geneviève M Labbé; Doris Quinkert; David J Pattinson; Heidi C L Spång; Simon J Draper; Bjarne Bogen; Ranveig Braathen
Journal:  Front Immunol       Date:  2021-10-18       Impact factor: 7.561

Review 5.  Plasmodium falciparum merozoite surface protein 3 as a vaccine candidate: a brief review.

Authors:  Késsia Caroline Souza Alves; Jander Matos Guimarães; Maria Edilene Martins de Almeida; Luís André Morais Mariúba
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2022-03-11       Impact factor: 1.846

Review 6.  Malaria vaccines: identifying Plasmodium falciparum liver-stage targets.

Authors:  Rhea J Longley; Adrian V S Hill; Alexandra J Spencer
Journal:  Front Microbiol       Date:  2015-09-15       Impact factor: 5.640

Review 7.  Merozoite surface proteins in red blood cell invasion, immunity and vaccines against malaria.

Authors:  James G Beeson; Damien R Drew; Michelle J Boyle; Gaoqian Feng; Freya J I Fowkes; Jack S Richards
Journal:  FEMS Microbiol Rev       Date:  2016-01-31       Impact factor: 16.408

8.  Production of full-length soluble Plasmodium falciparum RH5 protein vaccine using a Drosophila melanogaster Schneider 2 stable cell line system.

Authors:  Kathryn A Hjerrild; Jing Jin; Katherine E Wright; Rebecca E Brown; Jennifer M Marshall; Geneviève M Labbé; Sarah E Silk; Catherine J Cherry; Stine B Clemmensen; Thomas Jørgensen; Joseph J Illingworth; Daniel G W Alanine; Kathryn H Milne; Rebecca Ashfield; Willem A de Jongh; Alexander D Douglas; Matthew K Higgins; Simon J Draper
Journal:  Sci Rep       Date:  2016-07-26       Impact factor: 4.379

9.  Accelerating the clinical development of protein-based vaccines for malaria by efficient purification using a four amino acid C-terminal 'C-tag'.

Authors:  Jing Jin; Kathryn A Hjerrild; Sarah E Silk; Rebecca E Brown; Geneviève M Labbé; Jennifer M Marshall; Katherine E Wright; Sandra Bezemer; Stine B Clemmensen; Sumi Biswas; Yuanyuan Li; Aadil El-Turabi; Alexander D Douglas; Pim Hermans; Frank J Detmers; Willem A de Jongh; Matthew K Higgins; Rebecca Ashfield; Simon J Draper
Journal:  Int J Parasitol       Date:  2017-01-30       Impact factor: 3.981

10.  Production, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells.

Authors:  Jing Jin; Richard D Tarrant; Emma J Bolam; Philip Angell-Manning; Max Soegaard; David J Pattinson; Pawan Dulal; Sarah E Silk; Jennifer M Marshall; Rebecca A Dabbs; Fay L Nugent; Jordan R Barrett; Kathryn A Hjerrild; Lars Poulsen; Thomas Jørgensen; Tanja Brenner; Ioana N Baleanu; Helena M Parracho; Abdessamad Tahiri-Alaoui; Gary Whale; Sarah Moyle; Ruth O Payne; Angela M Minassian; Matthew K Higgins; Frank J Detmers; Alison M Lawrie; Alexander D Douglas; Robert Smith; Willem A de Jongh; Eleanor Berrie; Rebecca Ashfield; Simon J Draper
Journal:  NPJ Vaccines       Date:  2018-08-17       Impact factor: 7.344
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.